皓元医药：公司旗下重庆皓元抗体偶联CDMO基地于2025年3月正式投产运营

Group 1 - The company, Haoyuan Pharmaceutical, announced that its Chongqing Haoyuan antibody-drug conjugate (ADC) CDMO base will officially start operations in March 2025 and will pass the EU QP audit by June 2025 [2] - By the end of 2025, the international GMP system construction at the base is progressing smoothly, with a good number of ADC large molecule contracts signed and projects successfully delivered [2] - As orders increase, the company's capacity utilization rate is gradually improving [2]